You are here: Industry Insights > Alexion

News List

Alexion eyes $500M-plus in new Soliris sales with latest rare-disease win fiercepharma
September 25, 2018
Alexion has already seen major success expanding flagship Soliris into multiple indications. And it may just have another nod on the horizon.
Alexion to buy Wilson for $855m pharmatimes
July 17, 2018
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million.
Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline biospace
April 12, 2018
Alexion Pharmaceuticals, headquartered in New Haven, Connecticut, is buying Stockholm, Sweden-based Wilson Therapeutics for $855 million.
Alexion bids $855m for rare disease biotech Wilson Therapeutics pharmaphorum
April 12, 2018
Alexion wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $855 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease.
Alexion gears up to file new blood disorder drug pharmatimes
March 19, 2018
Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.
Alexion's Prospects Rise with Positive Phase III Trial Data biospace
March 16, 2018
Alexion Pharmaceuticals Inc., headquartered in New Haven, Connecticut, announced positive results from its pivotal Phase III clinical trial of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH).
Alexion bags Japanese approval for Soliris biospectrumasia
January 04, 2018
Soliris is the first and only approved Complement Inhibitor in Japan as a Treatment for Patients with Myasthenia gravis, a Chronic and Debilitating Neuromuscular Disorder
San Diego's Halozyme Lands Potential $680M R&D Deal With Alexion biospace
December 08, 2017
Halozyme Therapeutics, Inc. tied up a licensing agreement with Connecticut-based Alexion Pharmaceuticals that could net the company $680 million.
Alexion moves to bolster patent protection of Soliris pharmafile
August 18, 2017
It’s no wonder that the company is stacking its patent defences against any potential biosimilar encroachment onto its sales territory in the short term future.
Alexion and Sema4 partner in rare disease diagnostics pharmatimes
August 14, 2017
Alexion has partnered with Sema4 to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery.

Previous page 1 2 3 4 5 Next page